FDA Misses Electric Shock Ban Deadline, Advocates Voice Concerns

Key Takeaways

• FDA proposed on March 25, 2024, to ban ESDs for self-injurious or aggressive behavior as presenting unreasonable and substantial risk.
• Public comment closed May 28, 2024; FDA said it would then decide whether to finalize—without publishing a new final-rule date on its announcement page.
• FDA estimates about 50 people have ESD treatment plans, concentrated at the Judge Rotenberg Education Center.
• A prior 2020 ban was vacated in court; Congress later clarified FDA’s authority to ban specific intended uses.

What Did the FDA Propose in March 2024?

In a March 25, 2024 FDA announcement, the agency proposed banning electrical stimulation devices intended to reduce or stop self-injurious or aggressive behavior. FDA determined the devices present an unreasonable and substantial risk of illness or injury, including psychological harms such as depression, anxiety, PTSD, and physical harms such as pain and burns.

If finalized, the devices would no longer be considered legally marketed for those intended uses. Reuters reported the same day that this was FDA’s second attempt after a prior ban was annulled in court.

Why Has Finalization Dragged Past the Comment Window?

FDA stated the proposal would take comments until May 28, 2024, then the agency would review comments before deciding on a final rule. That comment window is a hard, sourced date. What is not sourced on allowlisted primaries is any later self-imposed calendar deadline for finalization. The operational fact advocates emphasize is the gap: comment closed in May 2024, and mid-2026 FDA materials still present the action as a proposal.

The Federal Register proposed rule (March 26, 2024) explains the legal backdrop: the D.C. Circuit vacated the 2020 ban in Judge Rotenberg Educational Center v. FDA, and Congress later amended the FD&C Act via FDORA to clarify FDA may ban a device for one or more intended uses.

Who Is Affected if the Ban Is Finalized?

FDA estimates around 50 individuals currently have a treatment plan that includes use or potential use of an ESD, and identifies the Judge Rotenberg Education Center in Canton, Massachusetts, as the only U.S. facility known to use these devices for this purpose. FDA said it intends to consider patient transition needs if it finalizes the ban.

• ~50 individuals with ESD treatment plans (FDA estimate)
• Single known U.S. facility: Judge Rotenberg Education Center
• Comment deadline: May 28, 2024

What Are the Implications for Medical Device Companies?

Even while unfinished, the proposal signals FDA willingness to use the rare device-ban authority for ethically contested aversive technologies. Companies developing behavioral neuromodulation or related devices should assume heightened scrutiny of aversive mechanisms and document non-aversive alternatives in regulatory strategy.

ESG-focused investors may treat unresolved ban dockets as governance risk when portfolios touch facilities or technologies tied to coercive behavioral interventions.

What Remains Unproven?

Secondary outlets have attributed specific missed internal FDA deadlines in 2026. Those claims are not repeated here without an FDA or Federal Register primary. Sourced conclusions are limited to the March 2024 proposal, May 28, 2024 comment close, patient-count estimates, and the unfinished status reflected on FDA’s own proposal page.

Related NovaPharma coverage

• FDA animal-derived thyroid guidance by August 2026
• Global regulatory roundup June 1, 2026
• FDA flavored vape ban and pharma implications

How Does FDORA Change the Legal Path Versus 2020?

The Federal Register proposal recounts that after the 2020 ban, the Judge Rotenberg Educational Center challenged FDA’s authority. On July 6, 2021, the D.C. Circuit vacated that ban in Judge Rotenberg Educational Center, Inc. v. FDA, holding that then-existing statute did not permit banning a device for specific intended uses without banning all uses.

Congress responded in the Food and Drug Omnibus Reform Act of 2022 by amending section 516(a) of the FD&C Act to state expressly that FDA may ban a device for one or more intended uses, and that a device banned for those uses is not legally marketed. The March 2024 proposal is the agency’s second attempt under that clarified authority.

For device companies, the lesson is structural: ethical controversy alone does not guarantee a quick ban, but once Congress clarifies authority, FDA can re-propose with a cleaner statutory footing. The remaining uncertainty is calendar risk—how long notice-and-comment and internal clearance take after the May 28, 2024 comment close.

What Should Compliance and ESG Teams Do Now?

Until a final rule publishes, ESDs for self-injurious or aggressive behavior remain in a proposed-ban posture rather than a completed market withdrawal. Compliance teams tied to behavioral health facilities should inventory any aversive electrical devices, document alternative behavior plans, and track the FDA-2023-N-3902 docket for a final action.

ESG diligence should treat unfinished ban dockets as open human-rights risk, especially where care settings involve people with intellectual or developmental disabilities who may have limited ability to consent. Portfolio screens can flag exposure even when the commercial market is a single facility and roughly 50 treatment plans, because the reputational and legal downside is asymmetric.

Medtech developers working on neurostimulation for other indications should keep intended-use labeling precise. FDA’s proposal targets ESDs for self-injurious or aggressive behavior specifically; unrelated cleared stimulators are not automatically banned by this docket, but aversive-use creep in labeling or promotion would invite scrutiny under the same risk framework FDA articulated in March 2024.

Frequently Asked Questions

Primary Sources

1. FDA — Proposed ban on ESDs (Mar 25, 2024)
2. GovInfo — Federal Register proposed rule FR-2024-06037
3. Reuters — FDA proposes ban second time (Mar 25, 2024)